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The pseudotrisaccharide allosamidin is a potent fam-
ily 18 chitinase inhibitor with demonstrated biological
activity against insects, fungi, and the Plasmodium fal-
ciparum life cycle. The synthesis and biological proper-
ties of several derivatives have been reported. The
structural interactions of allosamidin with several fam-
ily 18 chitinases have been determined by x-ray crystal-
lography previously. Here, a high resolution structure
of chitotriosidase, the human macrophage chitinase, in
complex with allosamidin is presented. In addition, com-
plexes of the allosamidin derivatives demethylallosami-
din, methylallosamidin, and glucoallosamidin B are de-
scribed, together with their inhibitory properties.
Similar to other chitinases, inhibition of the human
chitinase by allosamidin derivatives lacking a methyl
group is 10-fold stronger, and smaller effects are ob-
served for the methyl and C3 epimer derivatives. The
structures explain the effects on inhibition in terms of
altered hydrogen bonding and hydrophobic interac-
tions, together with displaced water molecules. The data
reported here represent a first step toward structure-
based design of specific allosamidin derivatives.
Family 18 chitinases hydrolyze chitin, a polymer of -(1,4)-
linked N-acetylglucosamine. Chitin is not found in humans but
plays a key role in the life cycles of several classes of human
pathogens, such as fungi (1), nematodes (2), protozoan para-
sites (3), and insects (4). Several chitinase inhibitors with bio-
logical activity have been identified, such as allosamidin (5),
styloguanidines (6), and the cyclic peptides CI-4 (7–9), argifin
(10), and argadin (11, 12). Allosamidin (see Fig. 1) is a pseudo-
trisaccharide isolated from Streptomyces cultures (5). It con-
sists of two N-acetylallosamine sugars, linked to a novel moiety
termed allosamizoline, which contains a cyclopentitol group,
coupled to an oxazoline that carries a dimethyl amine (Fig. 1
and Table I). The inhibitor has been shown to inhibit all family
18 chitinases, with Ki in the nM to M range (13, 14). It inhibits
cell separation in fungi (1, 15), transmission of the malaria
parasite Plasmodium falciparum (3, 16, 17), and insect devel-
opment (13). Several natural allosamidin derivatives have been
isolated and characterized (reviewed in Refs. 13 and 14), and
the total synthesis of the inhibitor has been achieved through
several strategies (14).
The structure of allosamidin in complex with family 18 chiti-
nases has been solved for hevamine (18), chitinase B from
Serratia marcescens (19), and chitinase 1 from Coccidioides
immitis (20). A preliminary soaking study has also been re-
ported for the human chitinase (21). The inhibitor appears to
bind from the 3 to 1 subsites, with the allosamizoline occu-
pying the 1 subsite. Several hydrogen bonds and stacking
interactions with aromatic residues appear to be responsible
for the tight binding of allosamidin to the family 18 chitinases
(19, 20, 22). Allosamidin is thought to resemble the structure of
a reaction intermediate that is unique among the glycoside
hydrolases (18). Retaining glycoside hydrolases mostly function
through a double displacement mechanism that involves a
catalytic acid and a nucleophile and proceeds through a cova-
lent enzyme-substrate intermediate (such as shown recently
(23) for lysozyme). In family 18 chitinases, however, a suitable
nucleophile is missing in the protein, and instead the reaction
proceeds through nucleophilic attack of the N-acetyl group on
the substrate itself, resulting in an oxazoline intermediate (18,
19, 24, 25) that is stabilized by the conserved Asp neighboring
the catalytic Glu in the characteristic DXXDXDXE sequence
motif (Fig. 2). It is this intermediate that is mimicked by
allosamidin (Fig. 1). The inhibitor is hydrolytically stable, be-
cause it lacks the pyranose oxygen.
Allosamidin is a broad-spectrum inhibitor, inhibiting all
characterized family 18 chitinases. If allosamidin is to be used
as a pharmacophore for development of novel compounds with
activity against human pathogens, it is also necessary to take
into account the human macrophage chitinase identified re-
cently (26–28). This enzyme has endochitinase activity against
chitin azure and colloidal chitin (27, 29) and has been shown to
be able to degrade chitin from the Candida albicans cell wall
(29). Furthermore, 6% of the human population is homozygous
for an inactivated form of the gene (26, 30), which preliminary
studies have associated with an increased susceptibility to
nematodal infections (31). It has therefore been proposed that
the human chitinase plays a role in defense against chitinous
pathogens (29, 30). Thus, it would be necessary to design al-
losamidin derivatives with specific activity against chitinases
from pathogens but only weak inhibition of the human chiti-
nase. Several allosamidin derivatives are already available (13,
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14). Although complexes of family 18 chitinases with allosami-
din itself have been characterized (18–20), none of its deriva-
tives have been analyzed structurally in the context of a chiti-
nase. As a first step toward the design of specific allosamidins,
we describe here the crystal structures of the human chitinase
complexed with allosamidin (ALLO)1 and three derivatives,
demethylallosamidin (DEME), methylallosamidin (METH),
and glucoallosamidin B (GLCB) (Fig. 1). We also report the
inhibitory properties of these derivatives against human chiti-
nase, which, together with the structures, suggest that devel-
opment of a specific, yet still potent, allosamidin-based chiti-
nase inhibitor should be possible.
MATERIALS AND METHODS
Structure Determination—Human chitinase (HCHT) was isolated as
described previously (21). As reported earlier, soaking of HCHT crystals
with ALLO and its derivatives resulted in severe cracking (21). To
overcome these problems, HCHT was co-crystallized with ALLO and its
derivatives DEME, METH, and GLCB (Fig. 1). The complexes were
formed through addition of 10 mM allosamidin derivative to the protein,
which was at a concentration of 8 mg/ml. Crystals were then grown by
vapor diffusion using 1 l of protein-inhibitor complex and 1 l of
mother liquor consisting of 25% polyethylene glycol, 550 monomethyl
ether, 0.01 M ZnSO4, and 0.1 M MES, pH 6.5, equilibrated against a
reservoir containing 1 ml of mother liquor. Crystals appeared after 2
days and grew to a maximum size of 0.2  0.1  0.1 mm. The crystals
were cryoprotected in a solution of mother liquor containing 3 M Li2SO4
and then frozen in a nitrogen cryostream for data collection. Data were
collected on beamline ID14-EH2 at the European Synchrotron Radia-
tion Facility (Grenoble, France) and beamline X11 at the Deutsches
Elektronen Synchrotron (the Deutsches Elektronen Synchrotron, Ham-
burg, Germany), and processed with the HKL suite of programs (32)
(Table II). The HCHTALLO structure was solved by molecular replace-
ment with AMoRe (33) (search model, the native HCHT structure (21);
top solution, r  0.344; correlation coefficient, 0.694) and was used as a
starting structure for the refinement of the other complexes. Refine-
ment was performed with CNS (34) interspersed with model building
in O (35). Topologies for the allosamidins were obtained from the
PRODRG server (36). The inhibitors were not included until defined by
unbiased Fo  Fc,calc maps (Fig. 3).
Enzymology—The IC50 values (i.e. inhibitor concentration resulting
in 50% inhibition) of the allosamidin derivatives were determined using
the fluorogenic substrate 4-methylumbelliferyl--D-N,N,N-triace-
tylchitotriose (4MU-NAG3; Sigma) in a standard assay, as described
previously (26). Briefly, in a final volume of 125 l, a constant amount
of enzyme was incubated with 0.022 mM substrate in McIlvain buffer
(100 mM citric acid, 200 mM sodium phosphate, pH 5.2) containing 1
mg/ml bovine serum albumin, for 20 min at 37 °C in the presence of
different concentrations of inhibitor. After addition of 2.5 ml of 0.3 M
glycine-NaOH, pH 10.6, the fluorescence of the liberated 4MU was
quantified using a PerkinElmer Life Sciences LS2 fluorimeter (excita-
tion 445 nm, emission 366 nm). The ability of chitotriosidase to trans-
glycosylate does not allow determination of Ki values.
RESULTS AND DISCUSSION
Overall Structures—HCHT were grown in the presence of
ALLO, DEME, METH, and GLCB (Fig. 1). The crystals dif-
fracted to 1.85, 2.55, 2.60, and 2.55 Å, respectively. The struc-
tures were solved by molecular replacement using the native
HCHT structure as a search model (21) and refined to R-factors
(Rfree) of 0.181 (0.192), 0.215 (0.257), 0.211 (0.253), and 0.225
(0.275), respectively. Models for the allosamidins were only
included in the refinement, when they were well defined by
unbiased Fo  Fc ,calc density (Fig. 3). Analysis of Ramachan-
dran plots calculated with PROCHECK (37) reveal that there is
only one residue (Asp-328) in a disallowed conformation, yet
electron density for this residue is well defined.
The allosamidins bind in a groove on the chitinase, occupying
subsites 3 to 1 (Figs. 3 and 4). In the HCHTALLO complex,
a second, disordered, allosamidin molecule (average B-factors
40.1 Å2, compared with 20.8 Å2 for the first molecule) is ob-
served to bind to the protein, approximately occupying the 1
to 3 subsites. It is possible that this represents a weaker
binding interaction and only occurs because of the high concen-
trations (10 mM) of allosamidin in the mother liquor. Subse-
quent comparisons and discussions will focus on the ordered
allosamidin molecule only.
Three chitinaseallosamidin complexes have been reported
previously for hevamine (18), chitinase B from S. marcescens
(19), and chitinase 1 from C. immitis (20). In the HCHTALLO
structure, the inhibitor binds in the same location and orien-
tation as observed in these complexes. There are no significant
backbone conformational changes; the HCHTALLO complex
superimposes with an root mean square deviation of 0.36 Å on
the HCHT structure C atoms. The tightest interactions are
formed with the allosamizoline in the1 subsite, which is lined
with residues that are conserved in family 18 chitinases from a
wide range of organisms (Figs. 2 and 3). Trp-358 stacks with
the hydrophobic face of the allosamizoline, similar to the inter-
action of this residue with the 1 boat pyranose in the chiti-
nase B-NAG5 complex (19). Tyr-27, Phe-58, Gly-98, Ala-183,
Met-210, and Met-356 are the main contributors to a hydro-
phobic pocket, which is occupied by the two allosamizoline
methyl groups (Figs. 3 and 4). The allosamizoline moiety has
several hydrogen bonding interactions with the protein (see
Table IV). Asp-138 stabilizes the positive charge on the oxazo-
line (Fig. 3) and is flipped 180o around 1 compared with
the native structure (21), as also observed in all other
chitinaseALLO complexes (19, 20, 22). The backbone nitrogen
of Trp-99 hydrogen bonds the allosamizoline O3 (Fig. 3). On the
opposite side of the inhibitor, Tyr-212 and Asp-213 hydrogen
bond with the allosamizoline O7 and O6, respectively (Fig. 3).
In the chitinase BALLO structure, an ordered water mole-
cule was observed within 3.3 Å of the allosamizoline C1 carbon,
and subsequent analysis of the hevamineALLO complex also
revealed such a water molecule (19). A similar water molecule
is also found upon inspection of the C. immitis CTS1ALLO
complex published recently (20). This interaction is thought to
be reminiscent of the attack of a water molecule, which hydro-
lyzes the oxazolinium ion reaction intermediate (19). However,
1 The abbreviations used are: ALLO, allosamidin; DEME, demethyl-
allosamidin; METH, methylallosamidin; GLCB, glucoallosamidin B;
HCHT, human chitinase; MES, 4-morpholineethanesulfonic acid.
TABLE I
Substitutions of allosamidin and its derivatives
R1 R2 R3 R4
Allosamidin (ALLO) CH3 H OH H
Demethylallosamidin
(DEME)
H H OH H
Methylallosamidin
(METH)
CH3 CH3 OH H
Glucoallosamidin B
(GLCB)
H CH3 H OH
FIG. 1. Allosamidin and its derivatives. The two-dimensional
chemical structure of the allosamidin backbone is shown. Depending on
the substitutions on R1-R4 the following naturally occurring derivatives
are discussed in this study.
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this water molecule is not observed in the complexes with the
allosamidins described here. In the HCHTALLO complex, the
position of this water molecule is occupied by the N-acetyl
group of the second disordered allosamidin molecule. The rel-
atively low resolution diffraction data for the complexes with
the allosamidin derivatives may not be sufficient to define the
position of this particular water molecule.
Although the allosamizoline moiety tightly binds conserved
residues through hydrogen bonding and hydrophobic interac-
tions, there are fewer interactions with the two N-acetylal-
losamine sugars in the 2 and 3 subsites (see Table IV). The
sugar in the 2 subsite makes two hydrogen bonds to Asn-100,
via the O4 and O6 atoms (Fig. 3). Further hydrogen bonds are
formed from O3 to Glu-297 and from Trp-358 to O7. The methyl
TABLE II
Details of data collection and structure refinement
Values in parentheses are for the highest resolution shell. Crystals were of space group P43212 and were cryo-cooled to 100 K. All measured data
were included in structure refinement.
ALLO DEME METH GLCB
Cell dimensions (Å) a  94.86 a  93.83 a  93.99 a  94.14
b  94.86 b  93.83 b  93.99 b  94.14
c  83.48 c  86.90 c  87.09 c  88.43
Resolution range (Å) 25–1.85 (2.92–1.85) 25–2.55 (2.64–2.55) 25–2.60 (2.69–2.60) 25–2.55
No. observed reflections 201273 (13633) 63006 (6132) 54650 (5358) 52134 (5376)
No. unique reflections 32893 (3050) 13215 (1283) 12526 (1233) 13275 (1306)
Redundancy 6.1 (4.5) 4.8 (4.8) 4.4 (4.3) 3.9 (4.1)
I/I 15.9 (5.2) 11.3 (2.3) 11.4 (2.5) 11.3 (2.7)
Completeness (%) 99.3 (93.8) 99.6 (98.9) 99.9 (100.0) 98.7 (100.0)
Rsym (%) 4.8 (31.4) 10.3 (64.2) 9.4 (64.5) 8.3 (66.1)
Rcrys (%) 18.1 21.5 21.1 22.5
Rfrec (%) 19.2 25.7 25.3 27.5
No. Rfren reflections 675 260 246 261
No. protein atoms 2871 2877 2877 2877
No. water molecules 253 53 48 66
No. inhibitor atoms 86 42 44 43
Root mean square deviation from ideal geometry
Bonds (Å) 0.010 0.008 0.011 0.012
Angles (°) 2.0 1.4 1.6 1.9
B-factor Root mean square deviation (Å2)
(bonded, main chain) 1.4 1.5 1.5 1.6
Bprotein (Å
2) 27.4 42.9 44.3 46.7
Binhibitor (Å
2) 30.5 31.7 33.8 44.9
FIG. 2. Multiple sequence alignment of chitinases. Sequences of the human chitinase (HUMAN), S. cerevisiae CTS1 (YEAST), C. albicans
chitinases (consensus sequence; CANAL), T. harzianum chitinases (consensus sequence; TRIHA), and B. mori chitinase (BOMOR) were aligned
with T-coffee (41) and shaded with BOXSHADE. Numbering and secondary structure is according to the human chitinase. Triangles indicate
residues that form mainly hydrophobic (open) or hydrogen bonding (filled) interactions with allosamidin in the HCHTALLO complex (see also Fig.
3). The human, T. harzianum, and B. mori chitinases possess an extra / domain that is represented in the alignment by a gray box (after residue
265 for HCHT). This domain is absent in the S. cerevisiae and C. albicans chitinases.
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on the N-acetyl group binds in a hydrophobic pocket formed by
Tyr-267, Met-300, and Leu-362 (Fig. 3). The 3 sugar stacks
with Trp-31, whereas a hydrogen bond is formed with the side
chain of Glu-297 (Fig. 3). Two ordered water molecules mediate
several inhibitor-protein hydrogen bonds (Fig. 3). Residues
266–337 form the / domain in HCHT, which is absent in the
smaller family 18 chitinases such as hevamine and the fungal
chitinases (Figs. 2 and 4). Therefore, these smaller enzymes
have a more solvent exposed 2 subsite and almost no inter-
actions with the N-acetylallosamine at 3 (18).
Enzymology—A large number of allosamidin derivatives
have been synthesized and characterized for their biological
activity (reviewed in Refs. 13 and 14). Here, we have focused on
three derivatives (DEME, METH, and GLCB; Fig. 1) for which
enzymological data with several chitinases is already available
(compiled in Ref. 13) (Table III). We have determined the
apparent IC50 values of these derivatives against human chiti-
nase using a standard assay with the fluorescent substrate
4-methylumbelliferyl-chitotriose (4MU-NAG3) (Table III). The
IC50 for ALLO (40 nM) has been reported previously (38). Re-
moval of one of the methyl groups on the allosamizoline moiety
leads to an 20-fold increase in affinity (DEME; Fig. 1), com-
pared with ALLO. If an extra methyl group is added to the O6
hydroxyl on the 3 allosamine, a similar increase in inhibition
is observed (METH; Fig. 1 and Table III). If both these modi-
fications are combined together with epimerization at carbon
C3, only a 5-fold stronger inhibition is measured (GLCB; Fig. 1
and Table III), compared with ALLO. These data (together with
other demethylallosamidin derivatives not discussed here (13))
suggest that the major effect on inhibition is the large increase
FIG. 3. Complexes with allosamidin
derivatives. Stereo images of the final
structures of the human chitinase in com-
plex with allosamidin and its derivatives
are shown. Side chains interacting with
the allosamidins (also indicated in Fig. 2)
are shown in a sticks representation. The
allosamidins are shown as a sticks model
with orange carbons. Water molecules in-
volved in allosamidin hydrogen bonds are
shown as red spheres. Hydrogen bonds
are shown as dotted green lines and are
listed in Table IV. The unbiased
Fo  Fc ,calc maps before inclusion of
models for the inhibitors in the refine-
ment are shown in magenta, contoured at
2.25 .
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in binding upon removal of one of the methyl groups on the
allosamizoline moiety. The inhibition data of these derivatives
on other chitinases (Table III) shows that there are two differ-
ent classes: one that, similar to HCHT, shows a 10–100-fold
drop for DEME compared with ALLO (the chitinases from S.
cerevisiae and C. albicans) and another that does not show this
effect (the chitinases from Trichoderma harzianum and Bom-
byx mori). In addition, HCHT and the chitinases from T. har-
zianum and B. mori bind ALLO 10–1000-fold better than the
fungal chitinases from S. cerevisiae and C. albicans. Inspection
of the HCHTALLO structure (Fig. 3) and a sequence alignment
(Fig. 2) reveals two potential reasons for this difference in
inhibition. First, the S. cerevisiae and C. albicans chitinases
are similar to the relatively small plant chitinase hevamine,
which lacks the extra / domain that gives the active site a
groove character and provides several contacts with the inhib-
itor (Tyr-267, Glu-297, and Met-300 in HCHT; Figs. 3 and 4). In
addition, Met-210 and Met-356, two hydrophobic residues that
form part of the pocket for the allosamizoline methyl groups,
are conserved in HCHT, T. harzianum, and B. mori chitinases
but replaced by more hydrophilic residues in the small fungal
chitinases.
Comparison of the Complexes—Despite the wealth of syn-
thetic and natural allosamidins described in the literature,
currently only complexes of family 18 chitinases with native
ALLO have been determined (19, 20, 22). The complexes of
HCHT with the DEME, METH, and GLCB allosamidin deriv-
atives (Fig. 1) show no significant backbone conformational
changes and superimpose with root mean square deviations of
0.32, 0.31, and 0.32 Å on HCHT C atoms, respectively. Anal-
ysis of the binding pocket shows that although several key
hydrogen bonds are conserved (Table IV and Fig. 3), there are
differences in hydrogen bonding and side chain conformation.
Demethylallosamidin—In the HCHTDEME structures,
where the allosamidin lacks one of the methyl groups on the
allosamizoline (Fig. 1), the remaining methyl group points to-
ward the oxygen side of the oxazoline ring, creating a small
void that is filled by Glu-140 and Asp-138 rotating up to 30
TABLE III
Apparent IC50 values of the allosamidin derivatives against
chitinases from different species
IC50 values of human chitinase were determined by variation of
inhibitor concentrations. Assays were performed as described under
“Materials and Methods.” All constants are expressed in nM. IC50 values
for S. cerevisiae, C. albicans, T. harzianum, and B. mori were taken
from Ref. 13.
S. cerevisiae C. albicans T. harzianum B. mori Human
ALLO 55000 10000 1300 48 40
DEME 480 1100 1300 81 1.9
METH 60000 14000 1900 65 2.6
GLCB 810 1300 2600 65 8.0
TABLE IV
HCHT-inhibitor hydrogen bonds
Hydrogen bonds between the protein and inhibitor were calculated with WHAT IF (39) using the HB2 algorithm (40). This algorithm gives a 0
(no hydrogen bond) to 1 (optimal hydrogen bond) score to reflect hydrogen bond geometry (40) (HB2 column). A cut-off of 0.3 was applied here to
exclude weak hydrogen bonds. Inhibitor hydrogen bonding potential was calculated with PRODRG (36). Donor acceptor distances in Å are also
listed (D-A).
Atom
1 subsite 2 subsite 3 subsite
Protein/water D-A HB2 Protein/water D-A HB2 Protein/water D-A HB2
N2 ALLO Asp-138, O2 2.73 0.68
DEME Asp-138, O2 2.77 0.72 H2O 3.03 0.89
METH Asp-138, O2 2.67 0.57 H2O 3.12 0.81
GLCB Asp-138, O2 2.52 0.54
O3 ALLO Trp-99, N 3.01 0.85 Glu-297, Oc1 3.03 0.47 H2O 2.60 0.46
DEME Trp-99, N 2.94 0.82 H2O 2.77 0.78
METH Trp-39, N 2.89 0.80
GLCB Trp-99, N 3.01 0.69 H2O 2.90 0.87
O4 ALLO Asn-100, N2 2.93 0.43
DEME H2O 2.63 0.92
METH Asn-100, N2 3.54 0.34
GLCB
O5 ALLO H2O 3.27 0.58
DEME
METH
GLCB
O6 ALLO Asp-213, O2 2.49 0.71 H2O  Asn-100, N 2.59,3.13 0.82,0.73 H2O 3.21 0.31
DEME Asp-213, O2 2.58 0.76 H2O  Asn-100, N 2.69,3.20 0.90,0.64 Glu-297, O1, H2O 2.42,2.64 0.60,0.60
METH Asp-213, O2 2.77 0.85 H2O  Asn-100, N 2.89,3.22 0.81,0.79
GLCB Asp-13, O2 2.83 0.69 Asn-100, N 3.02 0.87
O7 ALLO Tyr-212, O	 3.03 0.93 H2O  Trp-358, Nc1 2.90,2.67 0.62,0.58 Asn-100, N2, H2O 3.13,3.05 0.64,0.62
DEME Tyr-212, O	 3.18 0.92 H2O  Trp-358, Nc1 2.88,2.66 0.69,0.53 Asn-100, N2 2.43 0.42
METH Tyr-212, O	 3.14 0.90 H2O  Trp-358, Ne1 3.10,2.64 0.62,0.44
GLCB Tyr-212, O	 2.99 0.98 Trp-358, Ne1 2.67 0.56
FIG. 4. Sequence conservation in the active site. Stereo image
of the molecular surfaces calculated from HCHT in the HCHTALLO
complex and hevamine in the hevamineALLO complex (18) is shown.
Blue surface corresponds to conserved residues (Fig. 2), which are
also shown as a sticks model. ALLO is shown as a sticks model with
green carbons. The / domain, absent in hevamine, is indicated in
HCHT.
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degrees around 1/2. This brings the Asp-138 O2 atom closer to
the allosamizoline nitrogen that carries the remaining methyl
group, almost allowing formation of a hydrogen bond (distance
3.7 Å) (Fig. 3). This could explain the observed increase in
affinity that is observed for DEME (Table III). There are no
further noticeable conformational changes in the 1 binding
site. The residues surrounding the allosamizoline moiety are
the only ones that are highly conserved in family 18 chitinases
(Figs. 2–4). Analysis of sequence differences does not reveal an
amino acid change that is consistent with the different changes
in inhibition when comparing ALLO and DEME binding to a
range of chitinases (Table III). However, residues 95, 208, 210,
and 356 do form part of the hydrophobic pocket for the al-
losamizoline methyl groups and are not conserved. It is possi-
ble that several concerted changes at these positions are re-
sponsible for the two types of effects on inhibition (i.e. no
change or 10–100-fold stronger inhibition; Table III) for
DEME.
Methylallosamidin—The structure of the HCHTMETH com-
plex reveals that introduction of a methyl group on O6 of the
3 allosamine displaces an ordered water molecule from the
binding pocket (Figs. 1 and 3). This ordered water molecule
hydrogen bonds with DEME but not with ALLO (and is there-
fore not shown in Fig. 3-ALLO). In HCHT, addition of the
methyl group to ALLO appears to increase the inhibition (Ta-
ble III). A possible explanation could be the entropic gain
through displacement of the ordered water molecule, yet a
similar effect is not observed in the other chitinases (Table III).
In the absence of structural data for these chitinases it is
difficult to explain this, in particular because the entire /
domain is missing in the smaller fungal chitinases (Fig. 2).
Glucoallosamidin B—In the GLCB derivative three modifi-
cations are combined: removal of one of the allosamizoline
methyls (as in DEME), addition of a methyl on O6 of the 3
allosamine (as in METH), and epimerization of the 2 al-
losamine to a glucosamine (Fig. 1). The HCHTGLCB complex
(Fig. 3) shows several changes compared with the HCHTALLO
complex. In general, the GLCB molecule appears to be shifted
about 0.5 Å toward the reducing end of the binding cleft (Fig.
3). This leads to weakening of the key hydrogen bonds in the
1 subsite (Table IV), which may be partially responsible for
the weaker inhibition of HCHT, compared with the DEME and
METH derivatives. Also, changes similar to those in the
HCHTDEME (rotation of Asp-138 and Glu-140) and the
HCHTMETH complex (displacement of an ordered water mol-
ecule) are observed (Fig. 3). In addition, the equatorial O3
oxygen is no longer able to hydrogen bond another ordered
water molecule observed in the HCHTALLO complex. The
displacement of this water molecule leads to the loss of the
water-mediated hydrogen bond with Arg-269 (Fig. 3). At
the same time, however, the equatorial configuration of the O3
hydroxyl allows formation of the hydrogen bond with the pyr-
anose oxygen of the 3 sugar, which is generally found in
glucopolymers. The trends observed in the GLCB inhibition
data (Table III) are similar to those for DEME, suggesting that
removal of one of the allosamizoline methyls is the dominating
effect.
Design of Specific Allosamidin Derivatives—Inhibition data
of allosamidin and its derivatives show that there are signifi-
cant differences in inhibition against the different chitinases
(Table III). This suggests that if allosamidin is used as a tem-
plate in novel synthetic studies aimed at designing derivatives
against a specific chitinase, it would be possible to engineer a
certain degree of specificity. This is important if such deriva-
tives are used as antibiotics against human pathogens, as these
molecules should not inhibit human chitinase, which has been
suggested to be part of an innate defense against chitinous
pathogens (29–31). The structures described here allow for an
evaluation of the potential for structure-based design of specific
allosamidins. When sequence conservation is interpreted in the
context of the HCHTALLO complex (Fig. 4) it appears that the
only residues that are conserved and form part of the binding
site are those interacting with the allosamizoline (Figs. 2–4).
This would suggest it is difficult to make allosamizoline deriv-
atives that are specific for certain chitinases. Yet not all resi-
dues contacting the allosamizoline are conserved (Fig. 2), and
the differential inhibition for the DEME derivative (Table III)
demonstrates it is possible to exploit these differences. For
instance, Asn-100 makes hydrogen bonding interactions with
the 2/3 sugars (Fig. 3 and Table IV) yet is only present in
the human chitinase. In general, there is no sequence conser-
vation in the residues surrounding the 2 and 3 subsites
(Figs. 2 and 4). This is especially true for the smaller S. cerevi-
siae and C. albicans chitinases, which lack the extra / do-
main that harbors several residues that are seen to interact
with the allosamidins in the complexes described here (Figs.
2–4 and Table IV). Thus, the binding site in HCHT has a deep
groove character, whereas in hevamine (and the closely related
small fungal chitinases) it is a shallow pocket (22) (Fig. 4).
Hence, it should be possible to design derivatives that have
larger groups on the2 and3 sugars, fitting only the smaller,
more open, chitinases. Alternatively, moieties could be intro-
duced that interact specifically with side chains lining the
deeper grooves of the larger chitinases.
Recently, an additional mammalian chitinase has been de-
scribed that is mainly expressed in the stomach (29). This
protein has 52% sequence identity with the human macro-
phage chitinase and also contains the additional / fold. Given
the different expression patterns and the fact that this addi-
tional mammalian chitinase has a pH optimum of around 2, it
is likely that it plays a different role than the human macro-
phage chitinase and has enough sequence differences to allow
development of chitinase-specific inhibitors.
CONCLUSIONS
The structures of the human chitinase in complex with al-
losamidin and its derivatives have given new insights into the
molecular mechanisms and specificity of these potent family 18
chitinase inhibitors. The dimethyl derivative, 10- to 100-fold
more potent than allosamidin against most chitinases, appears
to bind more strongly because of possible extra interactions
with conserved residues that are part of the family 18 chitinase
sequence signature. Modifications of the 2 and 3 N-acetyl-
allosamines lead to displacement of ordered water molecules
and altered hydrogen bonding with the protein. The structures
could be used for further structure-based optimization of
allosamidin.
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